The ECOG-ACRIN Cancer Research Group today announced results from extended follow-up of patients in its randomized Phase 3 clinical trial, E1912. Previously untreated patients (aged 70 or younger) with chronic lymphocytic leukemia (CLL) who received ibrutinib-based therapy lived longer and with sustained benefit, compared to standard FCR chemoimmunotherapy. The updated analysis supports the earlier trial findings (Shanafelt, New England Journal of Medicine, August 2019).
E1912 follow-up shows ibrutinib effective, well tolerated by majority of CLL patients
- EurekAlert
- 7. 12 2019 (06:00)